The GLP receptor agonist class has expanded rapidly over the last decade. Three generations of research compounds — single-receptor, dual-receptor, and triple-receptor agonists — are now in active study. This article compares them in a research context.
Note on framing: this article describes published research on receptor binding, mechanism, and pharmacological characterization. It does not make claims about clinical effects, treatment outcomes, or any human application. All information is research-only and not medical advice.
The Receptors
Three receptors are relevant to this peptide class:
- GLP-1R (Glucagon-Like Peptide-1 Receptor) — expressed primarily in pancreatic β-cells, brain regions, and parts of the gastrointestinal tract
- GIPR (Glucose-dependent Insulinotropic Polypeptide Receptor) — expressed primarily in pancreatic β-cells and adipose tissue
- GCGR (Glucagon Receptor) — expressed primarily in hepatocytes and to a lesser extent in adipose tissue
All three are class B G-protein coupled receptors. Native peptide ligands (GLP-1, GIP, glucagon) bind their respective receptors with nanomolar affinity in research assays.
Generation 1 — Single-Receptor GLP-1 Agonists
Representative research compound: Semaglutide
Semaglutide is a GLP-1 analog with structural modifications (an albumin-binding fatty acid chain at position 26) that extend its half-life from minutes (native GLP-1) to multi-day kinetics in research models. It binds GLP-1R selectively, with minimal cross-reactivity at GIPR or GCGR in published binding assays.
The compound has been characterized extensively in animal model and pharmacology research since its development. Published studies report in vitro EC50 values in the low picomolar range for GLP-1R activation.
Generation 2 — Dual GLP-1/GIP Agonists
Representative research compound: Tirzepatide
Tirzepatide is a 39-amino-acid synthetic peptide engineered to activate both GLP-1R and GIPR simultaneously. It has approximately 5× selectivity for GIPR over GLP-1R based on published binding data, but activates both receptors at therapeutically relevant concentrations.
The dual-receptor design is based on research observations that combining GLP-1 and GIP receptor activation produces effects that exceed the sum of single-receptor activation alone — a synergy that has been characterized in pancreatic β-cell research and adipocyte studies.
Like Semaglutide, Tirzepatide is engineered for extended half-life via fatty acid attachment, supporting weekly research administration in animal models.
Generation 3 — Triple Agonists (GLP-1/GIP/Glucagon)
Representative research compound: Retatrutide
Retatrutide is a 39-amino-acid synthetic peptide engineered to activate all three receptors — GLP-1R, GIPR, and GCGR. Published binding data shows roughly equipotent activation of GLP-1R and GIPR with somewhat lower (but still significant) GCGR activation.
Adding glucagon receptor agonism introduces hepatic energy expenditure pathways that are not engaged by GLP-1 or GIP receptor activation alone. The pharmacological hypothesis driving triple-agonist research is that this combined receptor profile produces effects beyond what dual agonism alone achieves — particularly relevant in the context of energy balance research.
Retatrutide is the most-cited compound in current GLP-3 (triple-agonist) literature and is the most-researched triple-agonist peptide commercially available for research.
Side-by-Side Research Profile Summary
| Compound | Receptors | Selectivity Profile | Research Half-Life | Generation |
|---|---|---|---|---|
| Semaglutide | GLP-1R | GLP-1 selective | ~1 week | 1 (single) |
| Tirzepatide | GLP-1R + GIPR | ~5× GIP-favored | ~5 days | 2 (dual) |
| Retatrutide | GLP-1R + GIPR + GCGR | Roughly balanced GLP/GIP, lower GCGR | ~6 days | 3 (triple) |
Reconstitution and Storage Notes (Common Across the Class)
All three compounds are typically supplied lyophilized in vials sized 5–60 mg. Standard reconstitution practice:
- BAC water, 2 mL per 10 mg of peptide → 5 mg/mL concentration
- Storage: lyophilized vials room-temp stable for transit, refrigerated for medium-term, frozen for long-term
- Reconstituted: refrigerated at 36–46°F, 30–60 day stability with bacteriostatic preservative
Use the reconstitution calculator for syringe-unit conversions on any size and concentration.
QC Considerations Specific to This Class
The peptides in the GLP class are 30–40 amino acids long, which puts them at the upper end of solid-phase peptide synthesis difficulty. Achieving ≥99% purity requires:
- Precise control of coupling efficiency at each residue
- Multi-stage HPLC purification (typically 2–3 rounds)
- Mass-spec confirmation of the full sequence (catching any deletion sequences)
- Endotoxin testing on the final purified product
Per-lot HPLC chromatograms are particularly important for this class because the synthesis is complex enough that batch-to-batch variation is real even from a competent manufacturer. Matte’s COAs are at matteprotocol.com/coas/, addressable by lot number.
Choosing Between Generations for Research
The choice depends on the research question:
- Single-receptor specificity studies: Semaglutide is the cleanest tool — minimal off-target receptor activation
- Dual-pathway synergy studies: Tirzepatide provides controlled GLP-1 + GIP co-activation
- Triple-pathway integrated metabolism studies: Retatrutide is the only commercially available triple-agonist peptide
- Comparative studies across the class: running all three in parallel allows direct potency and selectivity comparison
Matte Protocol stocks all three compounds across multiple sizes — full catalog at matteprotocol.com/shop/.
Research use only. Not for human consumption, veterinary use, or as food additives. The information in this article is intended for qualified researchers and does not constitute medical or veterinary advice. Statements have not been evaluated by the US FDA.